Optilume BPH System demonstrates sustained improvements in LUTS secondary to BPH
"The next-generation Optilume BPH Catheter System offers a safe and effective new, minimally invasive treatment for BPH, reducing urinary obstruction with a low rate of sexual or other adverse effects," says Steven A. Kaplan, MD.
FDA approves Optilume BPH System
The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH.
2023 AUA highlights in benign urology
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Urologist Ash Tewari appointed Surgeon-in-Chief of Tisch Cancer Hospital
Ash Tewari, MBBS, MCh, is Chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai.
Dr. Galsky updates on CheckMate 274 trial for muscle-invasive urothelial carcinoma
“The effect size for adjuvant nivolumab versus placebo across primary, secondary, and exploratory endpoints is all remarkably stable,” says Matthew D. Galsky, MD.
Researchers identify immune cell that helps kill bladder cancer tumors
The study also identifies potential ways to make immunotherapy more effective in this setting.
2 Clarke Drive Cranbury, NJ 08512